Lanadelumab for Treatment of COVID-19 Disease

Summary

So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.

Timeline

Start

2020-10-30

Primary completion

2021-02-25

Completion

2021-04-30

Drugs

Indications